The Personalized Treatment for Urticaria

Zuberbier, Torsten

doi:10.1007/978-3-662-45840-2_8

Cited by 2 publications

(6 citation statements)

References 21 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44 Given the individual responses to sgAH, 38,45 the choice of sgAH and the daily dose can be personalized. 115 Up to 30% of ColdU patients achieve a complete protection from cold-induced whealing when treated with high-dose sgAH. 45 However, sgAH therapy is unlikely to prevent ColdA in ColdU patients upon an extensive cold exposure.…”

Section: Treatment Of Coldumentioning

confidence: 99%

“…Given the individual responses to sgAH, 38,45 the choice of sgAH and the daily dose can be personalized 115 . Up to 30% of ColdU patients achieve a complete protection from cold‐induced whealing when treated with high‐dose sgAH 45 .…”

Section: Managementmentioning

confidence: 99%

“…9,45,132 Future studies aimed at the predictive biomarkers in ColdU are awaited, since predictive biomarkers for various treatments in ColdU are currently lacking (Table 1, Section 10). 115…”

Section: Treatment Of Coldumentioning

confidence: 99%

“… To assess ColdU activity 37 ; To obtain evidence for spontaneous remission 112 ; To identify ColdU patients with a high risk of ColdA, 35 who are likely to benefit from an early prescription of epinephrine autoinjectors, higher doses of sgAH and treatment with biologics, although treatment responses currently cannot be predicted; To guide cold avoidance in patients’ daily lives and work 45 ; To monitor therapeutic interventions (Supplementary materials, Table ) 36,43‐45,47,66,113,114 ; To develop personalized treatment plans for ColdU patients 115 …”

Section: Diagnostic Algorithmmentioning

confidence: 99%

“…• To develop personalized treatment plans for ColdU patients. 115 Threshold testing includes CTT and CSTT assessments (Section 5). CTT testing is performed with the standardized TempTest device, which consists of a single U-shaped piezoelectric element that generates a temperature range from 4°C to 44°C.…”

Section: Iag Nos Ti C Alg Orithmmentioning

confidence: 99%

See 4 more Smart Citations

Cold urticaria – What we know and what we do not know

Maltseva

Borzova

Fomina

et al. 2020

Allergy

View full text Add to dashboard Cite

Cold urticaria (ColdU) is a common form of chronic inducible urticaria characterized by the development of wheals, angioedema or both in response to cold exposure. Recent research and guideline updates have advanced our understanding and management of ColdU. Today, its pathophysiology is thought to involve the cold‐induced formation of autoallergens and IgE to these autoallergens, which provoke a release of proinflammatory mediators from skin mast cells. The classification of ColdU includes typical and atypical subtypes. We know that cold‐induced wheals usually develop on rewarming and resolve within an hour and that anaphylaxis can occur. The diagnosis relies on the patient's history and cold stimulation testing. Additional diagnostic work‐up, including a search for underlying infections, should only be done if indicated by the patient's history. The management of ColdU includes cold avoidance, the regular use of nonsedating antihistamines and the off‐label use of omalizumab. However, many questions regarding ColdU remain unanswered. Here, we review what is known about ColdU, and we present important unanswered questions on the epidemiology, underlying pathomechanisms, clinical heterogeneity and treatment outcomes. Our aim is to guide future efforts that will close these knowledge gaps and advance the management of ColdU.

show abstract

Section: Treatment Of Coldumentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

Section: Treatment Of Coldumentioning

confidence: 99%

Section: Diagnostic Algorithmmentioning

confidence: 99%

Section: Iag Nos Ti C Alg Orithmmentioning

confidence: 99%

See 3 more Smart Citations

Cold urticaria – What we know and what we do not know

Maltseva

Borzova

Fomina

et al. 2020

Allergy

View full text Add to dashboard Cite

show abstract

Chronic-induced urticaria; classification, actual aspects of diagnosis and therapy

Serdotetskova

Danilycheva

Fomina

et al. 2023

Russian Journal of Allergy

View full text Add to dashboard Cite

Chronic induced urticaria (CIndU) is a group of diseases characterized by the occurrence of itchy wheals and/or angioedema in response to specific triggers, such as mechanical irritation, exposure of high and low temperatures, vibration, as well as ultraviolet radiation of various spectrum, appearing for 6 or more weeks. This group of diseases is characterized by a long duration, a significant impact to the patients quality of life, as well as the risk of severe life-threatening reactions. Diagnosis of induced urticaria - patient-safe reproduction of symptoms by exposure to a trigger (temperature, mechanical, etc.). Currently, there are no registered medical devices in the Russian Federation for the threshold diagnosis of most physical forms of urticaria, which makes it difficult to diagnose and dynamically monitor the state of these groups of patients and the response to treatment. The question of therapy with CIndU also remains open, due to the insufficient effectiveness of the recommended and available methods of therapy. This article provides an rewiew of current literature data.

show abstract

The Personalized Treatment for Urticaria

Cited by 2 publications

References 21 publications

Cold urticaria – What we know and what we do not know

Cold urticaria – What we know and what we do not know

Chronic-induced urticaria; classification, actual aspects of diagnosis and therapy

Contact Info

Product

Resources

About